Nu-Metformin
Nu-Metformin Brand names, Nu-Metformin Analogs
Nu-Metformin Brand Names Mixture
- No information avaliable
Nu-Metformin Chemical_Formula
C10H13NO4
Nu-Metformin RX_link
http://www.rxlist.com/cgi/generic2/methyl.htm
Nu-Metformin fda sheet
Nu-Metformin msds (material safety sheet)
Nu-Metformin Synthesis Reference
No information avaliable
Nu-Metformin Molecular Weight
211.215 g/mol
Nu-Metformin Melting Point
300 oC
Nu-Metformin H2O Solubility
1000 mg/L
Nu-Metformin State
Solid
Nu-Metformin LogP
-1.849
Nu-Metformin Dosage Forms
Liquid for injection; Tablets for oral use (125 mg, 250 mg, or 500 mg)
Nu-Metformin Indication
For use in the treatment of hypertension.
Nu-Metformin Pharmacology
Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.
Nu-Metformin Absorption
Absorption from the gastrointestinal tract is variable but averages approximately 50%.
Nu-Metformin side effects and Toxicity
The oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.
Nu-Metformin Patient Information
No information avaliable
Nu-Metformin Organisms Affected
Humans and other mammals
